Business Wire

PA-BENTLEY-SYSTEMS

15.4.2021 00:06:06 CEST | Business Wire | Press release

Share
Bentley Systems Announces Acquisition of Mobility Simulation Leader INRO

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the acquisition of INRO Software, a global leader in multimodal transportation planning, traffic simulation, and mobility visualization software. The acquisition expands Bentley’s capabilities in the important growth area of mobility digital twins, just as countries including the U.S. are poised to make a generational investment in infrastructure, and as transportation systems must evolve faster to accommodate both urbanization and carbon reduction goals, and the transition to electric and autonomous vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005928/en/

INRO, based in Montreal, Quebec, Canada, has for more than 40 years contributed to the advancement of mobility simulation and modeling for metropolitan, regional, and national transport and transit operators and planning agencies. Users of its multimodal simulation offerings include some of the world’s busiest transit systems and metros, such as Transport for London, Transport for New South Wales, the Washington State Department of Transportation, the Swedish Transport Administration Trafikverket, and the public transport system of São Paulo SPTrans.

INRO’s products include Emme , a multimodal transportation planning system for urban, regional, and national transportation forecasting; Dynameq , a vehicle-based traffic simulation platform for city-wide traffic planning; and CityPhi , a mobility visualization solution providing data visualization and visual analytics of large-scale mobility and geospatial datasets.

Combining the capabilities of INRO’s advanced traffic and vehicle simulation with Bentley’s passenger and pedestrian simulation and civil design software, including CUBE, Streetlytics, LEGION, and OpenRoads, places Bentley in a very strong position to deliver comprehensive mobility digital twins of multimodal transportation systems at urban, metropolitan, regional, and national scale.

Advancing Mobility Digital Twins

Urban planners are seeking to understand the ongoing impacts—on transportation system performance, reliability, and accessibility—of the new opportunities and challenges of private and shared mobility, the propensity for cycling or walking, connected autonomous vehicles, and potential congestion charging. With respect to their traditionally circumscribed use of transportation modeling tools in isolation and only on occasion, multiple advantages are now attainable through mobility digital twins, which can be continuously updated with as-operated engineering conditions and with observed traffic data. Mobility digital twins bring these functions together so that infrastructure planning and simulations can be continuously valuable throughout engineering, construction, and operations.

The pandemic experience reinforces the resilience value of sustaining “evergreen” planning and engineering modeling and simulation to maintain fitness for purpose during unanticipated eventualities. With the priority now on “building back better,” it is increasingly recognized that the most economical way to augment infrastructure capacity, while accomplishing the needed energy transitions toward climate sustainability, is to optimize the utilization, configuration, and life extension of existing mobility assets, while adding integrated and appealing public transit options.

This requirement now sets the stage for mobility digital twins that need to be multimodal, need detailed dynamic traffic assignment and agent-based methods for veracity, and need to scale up to systemwide and regionwide—uniquely hallmarks of INRO. As the leader in infrastructure digital twins, Bentley’s iTwin platform can now bring together—with the best-validated aggregate and individual vehicle and pedestrian simulation—3D/4D continuous surveying and reality modeling, civil engineering and project delivery, and asset and network performance. Ultimately, the opportunity for digital cities is to save their constituents time in their day, while at the same time improving congestion and climate resilience, and safety.

“We are very pleased to welcome INRO to Bentley Systems,” said Robert Mankowski, senior vice president, digital cities, Bentley Systems. “Professor Michael Florian and his team led the research of advanced multimodal network modeling methods which helped establish state-of-the-art mobility simulation, and in this next generation his son Dan is leading its software future in our mobility digital twin advancement. With the addition of INRO and its world-class team, Bentley Systems can even better accelerate cities and regions in going digital to ‘build back better’!”

Dr. Michael Florian, founder of INRO, said, “Bentley is a recognized leader in transportation across the infrastructure lifecycle from planning and design to heavy civil construction and road network management. My colleagues and I are very excited to join Bentley and to help realize the vision shared by thousands of cities and urban regions throughout the world to improve their sustainability and quality of life.”

Image 1: Emme

Caption: Image produced with Emme (www.inrosoftware.com/emme ) using data from Metro (https://www.oregonmetro.gov/ )

Image 2: Dynameq

Caption: Image produced with Dynameq (www.inrosoftware.com/dynameq ) using data from SFCTA (https://www.sfcta.org/ )

Image 3: CityPhi

Caption: Image produced with CityPhi (www.inrosoftware.com/cityphi ) using data from http://www.andresmh.com/nyctaxitrips/

Image 4: INRO Products

Caption: INRO is a global leader in multimodal transportation planning, traffic simulation, and mobility visualization software

Video: Seattle synthetic travel demand model

Caption: Illustration of ~20 million activities completed over the course of a day by 3.6 million people from a synthesized travel demand model of the Seattle metropolitan region. Activities are shown as time-animated vertical extrusions of population movements colored by purpose. The heads-up display summarizes the visible population by current activity. Video prepared by INRO using CityPhi (www.inrosoftware.com/cityphi ). More information on source data, provided by PSRC, is available at https://www.psrc.org/activity-based-travel-model-soundcast .

About Bentley Systems

Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, and industrial facilities. Our offerings include MicroStation -based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annualized revenues of more than $800 million in 172 countries. www.bentley.com

© 2021 Bentley, the Bentley logo, AssetWise, CUBE, INRO, Emme, Dynameq, CityPhi, iTwin, LEGION, MicroStation, OpenRoads, ProjectWise, and Streetlytics are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye